ASCO 2022: Ibrutinib Added to Bendamustine/Rituximab for Older Patients With Mantle Cell Lymphoma
Posted: 06/03/2022 | By: Chase Doyle

Question 1 of 5

Older patients with mantle cell lymphoma who received ibrutinib in combination with bendamustine/rituximab and rituximab maintenance as first-line therapy had a median progression-free survival of how many years?

Choose 1